Manufacturing innovation is essential for monoclonal antibody affordability and access

Abstract

Biopharmaceutical manufacturing innovation is essential for making monoclonal antibodies affordable and accessible by overcoming critical cost and supply barriers. Importantly, innovation supporting regional production will be required to meet low- and middle-income country health needs and strengthen global resilience against future infectious disease outbreaks.